Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Human molecular genetics - 15 Jan 2013

Yao Chen, Johnson William M, Gao Yue, Wang Wen, Zhang Jinwei, Deak Maria, Alessi Dario R, Zhu Xiongwei, Mieyal John J, Roder Hanno, Wilson-Delfosse Amy L, Chen Shu G

Abstract excerpt

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Parkinson's disease (PD). To explore the therapeutic potential of small molecules targeting the LRRK2 kinase domain, we characterized two LRRK2 kinase inhibitors, TTT-3002 and LRRK2-IN1, for their effects against LRRK2 activity in vitro and in Caenorhabditis elegans models of LRRK2-linked neurodegeneration. TTT-3002...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animals, Genetically Modified
Share to Caenorhabditis elegans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Neurons

Share to Neurotoxins

Share to Parkinson Disease

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23065705
DOI: 10.1093/hmg/dds431
PMCID: PMC3526163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.PMID 23065705Read ↗

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.Semantic proximity Read ↗

LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.Semantic proximity Read ↗

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.Semantic proximity Read ↗

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's diseaseSemantic proximity Read ↗

Mutations in LRRK2 potentiate age-related impairment of autophagic fluxSemantic proximity Read ↗

Systemic characterization of aging-related phenotypes induced by wild-type and G2019S LRRK2 in Caenorhabditis elegans.Semantic proximity Read ↗

Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans.Semantic proximity Read ↗

Regulation of physiologic actions of LRRK2: focus on autophagy.Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read ↗

Leucine‐rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule‐associated protein 1B to ameliorate lysosomal dysfunction and parkinsonismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.